News You Can Use
Suven is into the design, manufacture and supply of bulk active, drug intermediates and fine chemicals, while Asian Clinical Trials provides services like phase II/ III/ IV clinical trials, post-marketing surveillance and clinical data management to pharmaceutical, biotechnology and medical device companies. Asian Clinical Trials was incorporated in April 2001 by Suven Life Sciences managing director Venkat Jasti. According to Jasti, this merger will enable seamless transition of projects from one phase to another. “This arrangement will ensure that all activities catering to the life sciences industry can be done under one roof,” Jasti told Business Standard. The merged entity will continue with the name of Suven Life Sciences and Asian Clinical Trials will function as a separate business unit under the company.
Jasti, however, declined to comment on the combined revenues of the merged entity. For the third quarter ended December 2005, Suven registered an increase of 94 per cent in its total income at Rs 27.11 crore from Rs 13.95 crore in the corresponding quarter last year. Its net profit for the third quarter surged by 181.57 per cent to Rs 3.21 crore as compared to Rs 1.14 crore in the previous corresponding quarter. Suven expects to file its first investigational new drug in the US before the end of 2006.
According to KK Shashikumar, general manager, (personal and administration), the new fibre line would cater to the needs of four board machines and two paper machines on the Sarapaka campus. He said the expansion would take the output capacity to 525,000 tonnes/yr with the aid of new machinery. The Bhadrachalam mill commissioned India’s only elemental chlorine free pulp mill with a capacity of 100,000 tonnes three years ago in September 2002.
The proposal to use the existing vehicles of viability gap funding and the India Infrastructure Finance Company Limited to create a window to provide equity participation and or viability gap funding to new ventures are "excellent schemes," she said. This will help make India globally competitive with other nations. The three-year window will help accelerate early investment.
Lauding the announcment of the Indian infrastructure policy with projects on international airports,investments on roads, power, it said these would provide the needed impetus for semiconductor manufacturing.
0 Comments:
Post a Comment
<< Home